Approach

A critical element in enabling our clients to take advantage of strategic opportunities globally is our ability to understand, evaluate and execute international transactions by developing strong management relationships through meetings in the US, Europe, Australia, Asia and Latin America.

Achelous Partners believes that undiscovered, valuable technologies and assets as well as talented people exist around the world. By focusing our efforts on navigating throughout the world to meet management teams and thoroughly grasping their technologies and strategic vision, we are uniquely capable of evaluating and proposing value enhancing ideas beyond our clients’ geographic borders.

To assist our clients with evaluating and implementing these global opportunities, Achelous Partners has drawn together a carefully composed team of highly experienced, highly motivated Merger & Acquisition specialists. Our team has a previous track record working at several highly regarded investment banks, law firms, funds and institutions, pharma and biotech companies and academia. The collective expertise and capabilities give us a strong, performance-driven approach from origination to execution in domestic and cross-border M&A transactions.

Ultimately, understanding our clients’ issues, working alongside management and fulfilling our commitment to provide clients with independent, unbiased advice and successful deal execution results in our fundamental goal of establishing long-term advisory relationships with clients.

  • June 2017
    has been acquired by
    The undersigned acted as financial advisor to Coté Orphan, LLC
  • May 2017
    has been acquired by
    The undersigned acted as financial advisor to PharmaCell B.V.
  • April 2017
    has been acquired by
    The undersigned acted as financial advisor to Emergo Group, Inc.
  • April 2017
    has been acquired by
    The undersigned acted as financial advisor to Calbiotech, Inc.
  • January 2017
    has been acquired by
    The undersigned acted as financial advisor to BioControl Systems, Inc.
  • August 2016
    has been acquired by
    The undersigned acted as financial advisor to SPEware Corporation
  • July 2016
    has acquired
    The undersigned acted as financial advisor to Sharps Compliance Corp.
  • June 2016
    has been acquired by
    The undersigned acted as financial advisor to Cisbio Bioassays
  • December 2015
    has acquired
    The undersigned acted as financial advisor to Abzena plc
  • December 2015
    has acquired
    The undersigned acted as financial adviser to Sharps Compliance Corp.
  • October 2015
    has been acquired by
    The undersigned acted as financial advisor to Kinesis Pharma BV
  • August 2015
    has been acquired by
    The undersigned acted as financial advisor to DIAsource ImmunoAssays SA
  • July 2015
    has acquired
    The undersigned acted as financial advisor to Sharps Compliance Corp.
  • March 2015
    has acquired
    The undersigned acted as financial advisor to Ansell Limited
  • July 2014
    has been acquired by
    The undersigned acted as financial advisor to IBL International Holding BV
  • July 2014
    has been acquired by
    The undersigned served as financial advisor to Phlexglobal Limited
  • June 2014
    has been acquired by
    The undersigned served as financial advisors to Pharmalink Consulting
  • December 2013
    has acquired assets from
    The undersigned acted as advisor to Valeant Pharmaceuticals International
  • August 2013
    has been acquired by
    The undersigned acted as financial advisor to Kirkegaard & Perry Laboratories Inc
  • July 2013
    has been acquired by
    The undersigned acted as financial advisor to The Anson Group LLC
  • July 2013
    has signed a definitive agreement to sell its orthopedic implant assets and business to
    an Apax Partners company The undersigned acted as financial advisor to Austofix Group Limited
  • July 2013
    has been acquired by
    The undersigned acted as financial advisor to Kreatech Holding B.V.
  • July 2013
    has been acquired by
    USD$10,000,000
    The undersigned acted as financial advisor to Matrical Bioscience Inc
  • May 2013
    has been acquired by
    The undersigned acted as advisor to Triangle Biomedical Sciences Inc.
  • August 2012
    has been acquired by
    The undersigned acted as advisor to JSW Life Sciences GmbH
  • March 2012
    has acquired assets from
    US$164M plus up to US$20M in milestones
    The undersigned acted as advisor to Valeant Pharmaceuticals International
  • December 2011
    invests in
    The undersigned acted as advisor to Ansell Limited for the investment
  • August 2010
    has been acquired by
    The undersigned acted as financial advisor to EnviroLogix, Inc.
  • March 2010
    has been acquired by
    USD$59,000,000
    The undersigned acted as financial advisor to Finnzymes Oy
  • December 2009
    has licensed its ReGet® drug delivery system for ophthalmic indications to
    The undersigned acted as financial advisor to BTG olc
  • October 2009
    has been acquired by
    The undersigned acted as financial advisor to Anaspec Inc.
  • August 2009
    has sold its HySolv™ drug delivery technology to
    The undersigned acted as financial advisor to BTG plc
  • January 2009
    has been acquired by
    The undersigned acted as financial advisor to the shareholders of Labcoat Limited
  • December 2008
    has acquired
    The undersigned is acting as financial advisor to Biocompatibles International
  • December 2008
    has acquired
    The undersigned rendered a Fairness Opinion to Affymetrix, Inc.
  • February 2008
    has been acquired by
    The undersigned is acting as financial advisor to Sigma Pharmaceuticals
  • January 2008
    has been acquired by
    The undersigned is acting as financial advisor to Panbio Limited
  • May 2007
    has acquired
    The undersigned acted as financial advisor to Ansell Limited
  • March 2007
    has sold its Human Health point-of-care diagnostic products business to
    The undersigned acted as financial advisor to Agenix Limited
  • February 2007
    Strategic alliance and investment of up to £32,100,000 in
    The undersigned acted as financial advisor to GeneMedix, PLC
  • December 2006
    Announced M&A advisory and restructuring
    The undersigned acted as financial advisor to Panbio Limited
  • December 2006
    has acquired
    The undersigned acted financial advisor to Novozymes A/S
  • August 2006
    has acquired
    The undersigned acted as financial advisor to Meditech Research Limited
  • July 2006
    has acquired Delta Biotechnology Ltd from
    The undersigned acted as financial advisor to Novozymes A/S
  • April 2006
    has assigned IP and granted distribution rights for its Animal Health business to
    The undersigned acted as financial advisor to Agenix Limited
  • October 2005
    M&A advisory and valuation analysis
    The undersigned acted as financial advisor to CogState Limited
  • September 2005
    NASDAQ listing of ADRs (American Depositary Receipts)
    The undersigned acted as advisor to Genetic Technologies Limited
  • June 2005
    NASDAQ listing of ADRs (American Depositary Receipts)
    The undersigned acted as advisor to ChemGenex Pharmarceuticals Limited
  • January 2005
    awarded to
    for its investment banking role in the creation of
  • December 2004
    has been acquired by
    The undersigned acted as financial advisor to AGT Biosciences Ltd.
Top